Sun Pharma Q1 results: Reports consolidated PAT of Rs 1,444 crore, meets estimates; revenues rise 28%
SECTIONS
Sun Pharma Q1 results: Reports consolidated PAT of Rs 1,444 crore, meets estimates; revenues rise 28%ETMarkets.com
Last Updated: Jul 30, 2021, 02:33 PM IST
Share
Synopsis
The company’s consolidated revenues in the quarter rose 28 per cent year-on-year to Rs 9,719 crore, which was sharply above analysts’ expectations.
Agencies
Analysts had expected the company to report consolidated net profit of Rs 1,470 crore for the reported quarter.
MUMBAI:
Sun Pharmaceutical Industries today reported a consolidated net profit of Rs 1,444 crore for the quarter ended June as against a consolidated net loss of Rs 1,655 crore in the year-ago quarter. Analysts had expected the company to report consolidated net profit of Rs 1,470 crore for the reported quarter.
Remdesivir shortage in Nagpur; Nitin Gadkari dials Sun Pharma chief
Remdesivir shortage in Nagpur; Nitin Gadkari dials Sun Pharma chief
After Nagpur reported a shortage of Remdesivir vaccine, Union minister Nitin Gadkari called up Sun Pharma s chief to arrange for the medicine.
advertisement
Union minister Nitin Gadkari (Photo: PTI)
Union minister Nitin Gadkari has called up Sun Pharma s chief to arrange for 10,000 injections of Remdesivir in Maharashtra s Nagpur in view of a shortage of the medicine in the city.
Remdesivir is considered a key anti-viral drug in the fight against Covid-19, especially in adult patients with severe complications.
A press release from Gadkari s office on Saturday said the Lok Sabha member from Nagpur spoke to Sun Pharma s Managing Director Dilip Shanghvi over phone to inform him about the situation here and appealed to him to make available the Remdesivir injections.
Coronavirus | Remdesivir shortage in Nagpur; Gadkari dials Sun Pharma chief
Updated:
Updated:
Mr. Gadkari also appealed to the people of Nagpur to follow all COVID-19 prevention protocols
Share Article
Mr. Gadkari also appealed to the people of Nagpur to follow all COVID-19 prevention protocols Union minister Nitin Gadkari has called up Sun Pharma s chief to arrange for 10,000 injections of Remdesivir in Nagpur in view of a shortage of the medicine here in Maharashtra.
Remdesivir is considered a key anti-viral drug in the fight against COVID-19, especially in adult patients with severe complications.
A press release from Mr. Gadkari s office on Saturday said the Lok Sabha member from Nagpur spoke to Sun Pharma s Managing Director Dilip Shanghvi over phone to inform him about the situation and appealed to him to make available the Remdesivir injections.
Remdesivir shortage in Nagpur; Nitin Gadkari dials Sun Pharma chief business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.
BW Businessworld
Sun Pharma, Officials Including Dilip Shanghvi Settle Case Of Alleged Market Norms Violation With SEBI
Sebi had received two whistleblower complaints, wherein allegations were made against Sun Pharmaceutical Industries Ltd (SPIL) and its wholly-owned subsidiary Sun Pharmaceutical Laboratories Ltd (SPLL), alleging that the firms had been diverting funds through its sole distributor in India, Aditya Medisales Ltd.
Photo Credit :
Sun Pharmaceutical Industries Ltd and its senior officials, including Managing Director Dilip Shanghvi, on Thursday settled with regulator Sebi a case pertaining to alleged violation of listing obligation and disclosure requirements norms.
According to separate settlement orders, Sun Pharmaceutical paid over Rs 56.11 lakh towards settlement charges and Shanghvi paid Rs 62.35 lakh.